Abstract | AIMS: METHODS AND RESULTS: A multicentre, double-blind trial was performed in patients presenting within 6 h and undergoing primary PCI for anterior (the primary analysis cohort, n = 1010 patients) or inferior (an exploratory cohort, capped at 166 patients) STEMI. Patients with anterior STEMI were randomized to placebo or one of three doses of delcasertib (50, 150, or 450 mg/h) by intravenous infusion initiated before PCI and continued for ∼2.5 h. There were no differences between treatment groups in the primary efficacy endpoint of infarct size measured by creatine kinase MB fraction area under the curve (AUC) (median 5156, 5043, 4419, and 5253 ng h/mL in the placebo, delcasertib 50, 150, and 450 mg/mL groups, respectively) in the anterior STEMI cohort. No treatment-related differences were seen in secondary endpoints of infarct size, electrocardiographic ST-segment recovery AUC or time to stable ST recovery, or left ventricular ejection fraction at 3 months. No differences in rates of adjudicated clinical endpoints (death, heart failure, or serious ventricular arrhythmias) were observed. CONCLUSIONS:
|
Authors | A Michael Lincoff, Matthew Roe, Philip Aylward, John Galla, Andrzej Rynkiewicz, Victor Guetta, Michael Zelizko, Neal Kleiman, Harvey White, Ellen McErlean, David Erlinge, Mika Laine, Jorge Manuel Dos Santos Ferreira, Shaun Goodman, Shamir Mehta, Dan Atar, Harry Suryapranata, Svend Eggert Jensen, Tamas Forster, Antonio Fernandez-Ortiz, Danny Schoors, Peter Radke, Guido Belli, Danielle Brennan, Gregory Bell, Mitchell Krucoff, PROTECTION AMI Investigators |
Journal | European heart journal
(Eur Heart J)
Vol. 35
Issue 37
Pg. 2516-23
(Oct 01 2014)
ISSN: 1522-9645 [Electronic] England |
PMID | 24796339
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: [email protected]. |
Chemical References |
- Biomarkers
- KAI 9803
- Peptides
- Protein Kinase Inhibitors
- Troponin I
- Creatine Kinase, MB Form
|
Topics |
- Aged
- Area Under Curve
- Biomarkers
(metabolism)
- Chemotherapy, Adjuvant
- Creatine Kinase, MB Form
(metabolism)
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Myocardial Infarction
(therapy)
- Peptides
(administration & dosage)
- Percutaneous Coronary Intervention
(methods)
- Pilot Projects
- Protein Kinase Inhibitors
(administration & dosage)
- Treatment Outcome
- Troponin I
(metabolism)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|